Lori Handy, MD, provides guidance in these areas, including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.
|Videos|June 10, 2018
A Vaccine for Clostridium difficile: What to Consider
Author(s)Contagion® Editorial Staff
Xingmin Sun, PhD, discusses aspects that need to be considered before developing a vaccine for Clostridium difficile.
Advertisement
Xingmin Sun, PhD, assistant professor, Molecular Medicine, University of South Florida, discusses aspects that need to be considered before developing a vaccine for Clostridium difficile.
Interview transcript (slightly modified for readability):
Clostridium difficile is a gram-positive toxin-producing spore-forming anaerobic bacteria. The major symptoms of the infection are intestinal inflammation and diarrhea. These effects are largely due to toxins. The major risk factor of infection is the disruption of the internal microflora caused by antibiotic therapy or by other means.
Currently,
When we are developing a vaccine [against this pathogen] we have to think about several aspects. First, we need to think about the major virulent factors we need to target, and we need to think about the symptoms of the disease. We [also] need to think about immunization routes—intramuscular or mucosal—as well as the target population.
Considering C difficile infections, [they are] enteric pathogens and we need to target the major virulent factors, which are the 2 toxins. In terms of the immunization route, we would prefer to use a mucosal route, in particular, the oral immunization route would be ideal because it is an enteric pathogen and the disease is in the intestines.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
SubscribeAdvertisement
Related to this article
A new study in infants challenges the long-standing belief about the pathogen’s effects in the youngest pediatric population. Senior author Joseph Zackular, PhD, provides insights around his work including how it reshapes gut development and offers potential intervention strategies to shield neonates.
A 39-year-old unvaccinated Franklin County woman has died after a recent measles diagnosis. Nationally, numbers continue to increase and the US has passed 4,000 cases.
The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.
The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4080 confirmed cases, 78% above all of 2025.
UTI guidelines are moving away from complicated or uncomplicated infections to localized or systemic classification terminologies. Guidelines author Zachary Nelson, PharmD, MPH, BCIDP, provides further insights on the changes including applying antibiograms, potential costs, and whether clinicians will embrace these new classifications.
Demonstrating a diagnostic test works is no longer enough. Clinicians and laboratories also need evidence on how to adopt it in everyday practice. Andrea Prinzi, PhD, MPH, SM(ASCP), explains how implementation science can help infectious disease and clinical microbiology teams turn evidence into routine care.
With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.
Advertisement
Advertisement